According to The World Health Organization (WHO) estimates, cardiovascular diseases cause the deaths of 12 million people every year. According to experts, more than 50 percent of these deaths could be avoided through preventive measures.* CBI’s summit brings together drug developers from leading pharma and biotech companies to discuss the latest scientific developments and breakthroughs for cardiovascular disease. Opportunities and challenges in preventative medicine are explored along with the preclinical and clinical case studies of novel pipeline products for the treatment of cardiovascular disease and risk.

* http://www.bio-pro.de/en/life/thema/04333/index.html

Must attend information includes:

MTP-Inhibition – New Directions for the Treatment of Hyperlipidemia
Clinical data on the evaluation of CETP inhibitors in clinical trials
Targeting Lp-PLA2 in Treating Atherosclerosis
Understand inflammation as a Therapeutic Approach to Cardio-Metabolic Disease
Clinical Imaging Biomarkers for Determining Progression and Regression of Cardiovascular Disease
Plus! An FDA Address on the Qualification of Biomarkers for Safety and Efficacy -Federico Goodsaid Ph.D., Associate Director for Operations in Genomics, Office of Clinical Pharmacology, Office of Translational Science, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

For more information or to register, please contact the Center for Business Intelligence toll free by phone at 1-800-817-8601 or via e-mail at cbireg@cbinet.com.